CytoMed Chairman Moves to Boost Personal Stake Through Private Share Purchases

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks CytoMed Therapeutics Limited ( (GDTC) ) has issued an announcement. On May 13, 2026, CytoMed Therapeutics Limited’s chairman and director, Choo Chee Kong, entered into a binding private share purchase agreement with an independent arm’s-length shareholder to acquire 112,000 ordinary shares for cash in a privately negotiated deal. The company was not a party to the transaction and received no proceeds, but Mr. Choo has signaled his intention to pursue further private negotiations with other independent shareholders to increase his stake, a move that may be read by investors as a vote of confidence in CytoMed’s prospects and governance. Because the share purchases occur outside the company and do not involve new issuance, the transactions will not dilute existing shareholders, though they may gradually shift control and voting power toward the chairman. Market participants will likely monitor subsequent disclosures to gauge the extent of Mr. Choo’s future acquisitions and any implications for corporate strategy or potential alignment between management and minority investors. Spark’s Take on GDTC Stock According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral. The score is held down primarily by weak financial performance (persistent losses, volatile revenue, and ongoing cash burn), with some support from an improved balance-sheet leverage position. Technicals remain bearish with the stock below key moving averages and negative MACD, though oversold RSI/Stoch slightly temper the downside. Valuation is difficult to support due to negative earnings and no dividend yield. To see Spark’s full report on GDTC stock, click here. More about CytoMed Therapeutics Limited CytoMed Therapeutics Limited is a Singapore-based biotechnology company, with its principal executive office at 1 Commonwealth Lane in Singapore. The company is listed in the United States as a foreign private issuer and files its periodic reports with the SEC under Form 20-F, reflecting its access to U.S. capital markets and global investor base. Average Trading Volume: 14,174 Technical Sentiment Signal: Sell Current Market Cap: $10.42M Learn more about GDTC stock on TipRanks’ Stock Analysis page.